{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:40:38Z","timestamp":1789479638628,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971524"],"award-info":[{"award-number":["81971524"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11739-023-03362-0","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:01:45Z","timestamp":1688734905000},"page":"1759-1767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients with continuation of csDMARDs: a real-life study"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-0266","authenticated-orcid":false,"given":"Wenhui","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"4","key":"3362_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","volume":"16","author":"F Buttgereit","year":"2020","unstructured":"Buttgereit F (2020) Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol 16(4):239\u2013246. https:\/\/doi.org\/10.1038\/s41584-020-0370-z","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"3362_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semarthrit.2020.09.016","volume":"51","author":"DL Conn","year":"2020","unstructured":"Conn DL (2020) The story behind the use of glucocorticoids in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 51(1):15\u201319. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.016","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3362_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"A Kerschbaumer","year":"2022","unstructured":"Kerschbaumer A, Sepriano A, Bergstra SA et al (2022) Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82(1):95\u2013106. https:\/\/doi.org\/10.1136\/ard-2022-223365","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3362_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/ard-2022-223358","volume":"82","author":"SA Bergstra","year":"2022","unstructured":"Bergstra SA, Sepriano A, Kerschbaumer A et al (2022) Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82(1):81\u201394. https:\/\/doi.org\/10.1136\/ard-2022-223358","journal-title":"Ann Rheum Dis"},{"key":"3362_CR5","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1136\/bmj.m4328","volume":"371","author":"ML Hetland","year":"2020","unstructured":"Hetland ML, Haavardsholm EA, Rudin A et al (2020) NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 371:4328. https:\/\/doi.org\/10.1136\/bmj.m4328","journal-title":"BMJ"},{"issue":"1","key":"3362_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2022) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3362_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3362_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J et al (2022) Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 81(1):41\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220651","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3362_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/art.41754","volume":"73","author":"K Bechman","year":"2021","unstructured":"Bechman K, Halai K, Yates M et al (2021) Nonserious infections in patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Arthritis Rheumatol 73(10):1800\u20131809. https:\/\/doi.org\/10.1002\/art.41754","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"3362_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/annrheumdis-2021-220112","volume":"80","author":"W Xie","year":"2021","unstructured":"Xie W, Huang H, Li G et al (2021) Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. Ann Rheum Dis 80(8):997\u20131003. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220112","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3362_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1136\/annrheumdis-2021-220403","volume":"80","author":"JM Maassen","year":"2021","unstructured":"Maassen JM, Dos Santos SR, Bergstra SA, Goekoop R, Huizinga TWJ, Allaart CF (2021) Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies. Ann Rheum Dis 80(9):1124\u20131129. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220403","journal-title":"Ann Rheum Dis"},{"issue":"10246","key":"3362_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","volume":"396","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Buttgereit F, Bernasconi C et al (2020) SEMIRA collaborators. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet 396(10246):267\u2013276. https:\/\/doi.org\/10.1016\/S0140-6736(20)30636-X","journal-title":"Lancet"},{"issue":"1","key":"3362_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40744-020-00270-z","volume":"8","author":"W Xie","year":"2021","unstructured":"Xie W, Li G, Huang H, Zhang Z (2021) How to define Boolean low disease activity in rheumatoid arthritis: experience from a large real-world cohort. Rheumatol Ther 8(1):289\u2013301. https:\/\/doi.org\/10.1007\/s40744-020-00270-z","journal-title":"Rheumatol Ther"},{"issue":"2","key":"3362_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10067-019-04807-8","volume":"39","author":"W Xie","year":"2020","unstructured":"Xie W, Li J, Zhang Z (2020) The impact of different criteria sets on early remission and identifying its predictors in rheumatoid arthritis: results from an observational cohort (2009\u20132018). Clin Rheumatol 39(2):381\u2013389. https:\/\/doi.org\/10.1007\/s10067-019-04807-8","journal-title":"Clin Rheumatol"},{"issue":"9","key":"3362_CR15","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/1756-185X.13651","volume":"22","author":"W Xie","year":"2019","unstructured":"Xie W, Li J, Zhang X, Sun X, Zhang Z (2019) Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018. Int J Rheum Dis 22(9):1670\u20131678. https:\/\/doi.org\/10.1111\/1756-185X.13651","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"3362_CR16","first-page":"820","volume":"36","author":"W Xie","year":"2018","unstructured":"Xie W, Li J, Zhang X et al (2018) Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016. Clin Exp Rheumatol 36(5):820\u2013828","journal-title":"Clin Exp Rheumatol"},{"key":"3362_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106405","volume":"184","author":"Z Feng","year":"2022","unstructured":"Feng Z, Fu L, Wang J, Zhu Y, He X, Zhou L, Zhou X (2022) Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 184:106405","journal-title":"Pharmacol Res"},{"issue":"10","key":"3362_CR18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","volume":"43","author":"J Fransen","year":"2004","unstructured":"Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43(10):1252\u20131255","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3362_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42(2):244\u2013257","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3362_CR20","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796\u2013R806","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3362_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2022-223413","volume":"75","author":"P Studenic","year":"2022","unstructured":"Studenic P, Aletaha D, de Wit M et al (2022) American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis 75(1):15\u201322. https:\/\/doi.org\/10.1136\/ard-2022-223413","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"3362_CR22","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1001\/jama.2021.4542","volume":"325","author":"S Lillegraven","year":"2021","unstructured":"Lillegraven S, PaulshusSundlis\u00e6ter N et al (2021) Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial. JAMA 325(17):1755\u20131764. https:\/\/doi.org\/10.1001\/jama.2021.4542","journal-title":"JAMA"},{"issue":"6","key":"3362_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jbspin.2020.06.001","volume":"87","author":"S Asai","year":"2020","unstructured":"Asai S, Takahashi N, Hayashi M et al (2020) Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab. Joint Bone Spine 87(6):596\u2013602. https:\/\/doi.org\/10.1016\/j.jbspin.2020.06.001","journal-title":"Joint Bone Spine"},{"issue":"1","key":"3362_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13075-017-1320-2","volume":"19","author":"SY Kawashiri","year":"2017","unstructured":"Kawashiri SY, Fujikawa K, Nishino A et al (2017) Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled. Arthritis Res Ther 19(1):108. https:\/\/doi.org\/10.1186\/s13075-017-1320-2","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"3362_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40744-022-00527-9","volume":"10","author":"W Xie","year":"2023","unstructured":"Xie W, Huang H, Zhang Z (2023) Dynamic characteristics and predictive profile of glucocorticoids withdrawal in rheumatoid arthritis patients commencing glucocorticoids with csDMARD: a real-world experience. Rheumatol Ther 10(2):405\u2013419. https:\/\/doi.org\/10.1007\/s40744-022-00527-9","journal-title":"Rheumatol Ther"},{"issue":"5","key":"3362_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102797","volume":"20","author":"N Petrovsk\u00e1","year":"2021","unstructured":"Petrovsk\u00e1 N, Prajzlerov\u00e1 K, Vencovsk\u00fd J, \u0160enolt L, Filkov\u00e1 M (2021) The pre-clinical phase of rheumatoid arthritis: from risk factors to prevention of arthritis. Autoimmun Rev 20(5):102797. https:\/\/doi.org\/10.1016\/j.autrev.2021.102797","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3362_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000262","volume":"2","author":"RM Fleischmann","year":"2016","unstructured":"Fleischmann RM, Huizinga TW, Kavanaugh AF et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2(2):e000262. https:\/\/doi.org\/10.1136\/rmdopen-2016-000262","journal-title":"RMD Open"},{"issue":"9","key":"3362_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274264","volume":"17","author":"M Movahedi","year":"2022","unstructured":"Movahedi M, Cesta A, Li X, Bombardier C (2022) OBRI investigators. Disease activity trajectories for early and established rheumatoid arthritis: real-world data from a rheumatoid arthritis cohort. PLoS ONE 17(9):e0274264. https:\/\/doi.org\/10.1371\/journal.pone.0274264","journal-title":"PLoS ONE"},{"issue":"2","key":"3362_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000270","volume":"2","author":"IC Scott","year":"2016","unstructured":"Scott IC, Ibrahim F, Lewis CM, Scott DL, Strand V (2016) Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. RMD Open 2(2):e000270. https:\/\/doi.org\/10.1136\/rmdopen-2016-000270","journal-title":"RMD Open"},{"key":"3362_CR30","doi-asserted-by":"publisher","first-page":"i1777","DOI":"10.1136\/bmj.i1777","volume":"353","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 353:i1777. https:\/\/doi.org\/10.1136\/bmj.i1777","journal-title":"BMJ"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03362-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-023-03362-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03362-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T08:27:03Z","timestamp":1694766423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-023-03362-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3362"],"URL":"https:\/\/doi.org\/10.1007\/s11739-023-03362-0","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Peking University First Hospital (IRB number 2014-785).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical committee approval"}},{"value":"Informed consent for publication was obtained from all the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}